Nanjing Zenkom Pharmaceutical Co., Ltd.

(1) Primary objective: To determine the time course of plasma concentration of the active metabolite azilsartan in healthy subjects after administration of acesartan potassium tablets developed by Nanjing Zhengke Pharmaceutical Co., Ltd. using a self-crossover design, and to estimate the corresponding pharmacokinetic parameters. The acesartan potassium tablets (trade name: EDARBI®, specification: 80 mg based on acesartan (C30H24N4O8)) produced by Takeda Pharma A/S and Takeda Ireland Ltd. were used as reference to evaluate the bioequivalence between the two preparations. (2) Secondary objective: To observe the safety of acesartan potassium tablets in healthy Chinese subjects.

(1) Primary objective: To evaluate the pharmacokinetic characteristics of the test and reference preparations after a single oral administration in healthy subjects in the fasting and fed state, using baricitinib tablets produced by Nanjing Zhengke Pharmaceutical Co., Ltd. as the test preparation (T) and baricitinib tablets (trade name: OLUMIANT®) licensed by Eli Lilly Nederland B.V. as the reference preparation (R), and to evaluate the bioequivalence of the two preparations. (2) Secondary objective: To evaluate the safety of the test and reference preparations in healthy subjects.

The main purpose of the study is to evaluate the pharmacokinetic characteristics of the test preparation of pilocarpine hydrochloride eye drops and the reference preparation of pilocarpine hydrochloride eye drops (Vuity). The secondary purpose of the study is to investigate the safety of the test preparation and the reference preparation after administration to the subjects.